Short answer
Day One Biopharmaceuticals, Inc. (DAWN) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 7.01 (Regulation FD Disclosure). EU positive opinion received for OJEMDA (tovorafenib) in pediatric low-grade glioma: key step toward conditional marketing authorization in Europe.
Day One Biopharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- EU positive opinion received for OJEMDA (tovorafenib) in pediatric low-grade glioma: key step toward conditional marketing authorization in Europe
- Target indication: relapsed/refractory BRAF-altered pediatric low-grade glioma, same label as US approval
- Ipsen holds exclusive ex-US commercialization rights under July 2024 license deal: EU approval would trigger Ipsen-driven revenue to DAWN (royalties/milestones)
- Conditional marketing authorization path signals regulatory urgency given unmet pediatric need: typically faster but requires confirmatory data post-approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Day One Biopharmaceuticals, Inc. 8-K filings
Get the next DAWN 8-K as it lands
Follow DAWN for push alerts, or ask the research agent what this filing means.